Quantum BioPharma Refutes Securities Law Allegations from Law Firms
Quantum BioPharma Ltd. has formally rejected what it calls vague and unsubstantiated claims by The Schall Law Firm and DJS Law Group regarding alleged securities law violations, stating the announcements appear designed to mislead investors and harm the company's reputation.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has issued a formal response rejecting what it described as vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company stated that the announcements lack factual detail or context and appear intended to mislead investors and provoke unwarranted concern.
The biopharmaceutical company said it is reviewing the conduct of both firms and their principals and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation. This response comes amid the company's ongoing work in developing treatments for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
Quantum BioPharma's portfolio includes innovative assets and biotech solutions with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS. This patented new chemical entity has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company also maintains strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Additionally, Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., while retaining ownership of 20.11% of the company as of March 31, 2025.
The agreement with Unbuzzd Wellness Inc. includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once this threshold is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
Investors seeking additional information about Quantum BioPharma can access the latest news and updates in the company's newsroom at https://ibn.fm/QNTM. The full press release detailing the company's response to the law firm allegations is available at https://ibn.fm/TsBbx.